Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 6/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | PDE6D | O43924 | 1/20 | 0.55 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.55 |
| ▸ | AKT1 | P31749 | 2/20 | 0.54 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.53 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | GCGR | P47871 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29482555 | 1.00 | HMGCR (0.55) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Phosphine SCHEMBL5468910 | 0.99 | HMGCR (0.54) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL28985364 | 0.91 | HMGCR (0.50) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL3445256 | 0.89 | HMGCR (0.56) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL28494229 | 0.89 | HMGCR (0.56) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL2690 | 0.89 | HMGCR (0.58) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL4914199 | 0.89 | HMGCR (0.56) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL28860507 | 0.89 | HMGCR (0.56) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL29482554 | 0.89 | HMGCR (0.58) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL16429676 | 0.88 | HMGCR (0.43) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109574938-B | Method for synthesizing rosuvastatin sodium | 安徽省庆云医药股份有限公司 | 2022-04-22 | — | — | CN | claimed |
| CN-110483412-B | Synthetic method of rosuvastatin tert-butyl ester | 安徽省庆云医药股份有限公司 | 2020-06-26 | — | — | CN | claimed |
| CN-110759868-A | Preparation method of rosuvastatin | 雅本化学股份有限公司 | 2020-02-07 | — | — | CN | claimed |
| CN-109574938-A | A kind of synthetic method of Rosuvastatin sodium | 安徽省庆云医药股份有限公司 | 2019-04-05 | — | — | CN | claimed |
| CN-108362813-A | A kind of method for detecting purity of principal component | 江苏悦兴医药技术有限公司 | 2018-08-03 | — | — | CN | claimed |
| WO-2010023678-A1 | A PROCESS FOR PREPARATION OF ROSUVASTATIN INTERMEDIATE | BIOCON LIMITED (IN) | 2010-03-04 | — | — | WO | claimed |
| CN-115819408-B | Method for synthesizing rosuvastatin key intermediate with high selectivity | 宿迁阿尔法科技有限公司 | 2024-09-06 | — | — | CN | disclosed |
| CN-114280181-B | Rosuvastatin intermediate and detection method of related substances thereof | 浙江海翔川南药业有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-117630236-A | Detection method of bromide | 湖南九典制药股份有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-115819408-A | Method for highly selectively synthesizing rosuvastatin key intermediate | 宿迁阿尔法科技有限公司 | 2023-03-21 | — | — | CN | disclosed |
| CN-109574938-B | Method for synthesizing rosuvastatin sodium | 安徽省庆云医药股份有限公司 | 2022-04-22 | — | — | CN | disclosed |
| CN-109574938-B | Method for synthesizing rosuvastatin sodium | 安徽省庆云医药股份有限公司 | 2022-04-22 | — | — | CN | disclosed |
| CN-114280181-A | Detection method of rosuvastatin intermediate and related substances thereof | 浙江海翔川南药业有限公司 | 2022-04-05 | — | — | CN | disclosed |
| WO-2010023678-A1 | A PROCESS FOR PREPARATION OF ROSUVASTATIN INTERMEDIATE | BIOCON LIMITED (IN) | 2010-03-04 | — | — | WO | disclosed |
| US-20090275752-A1 | Novel Process for Statins and its Pharmaceutically Acceptable Salts Thereof | MSN LABORATORIES LIMITED (IN) | 2009-11-05 | — | — | US | disclosed |
| US-20080255170-A1 | Process for the Synthesis of Rosuvastatin Calcium | LEK PHARMACEUTICALS D.D (SI) | 2008-10-16 | — | — | US | disclosed |
| EP-1912953-A1 | PROCESS FOR THE SYNTHESIS OF ROSUVASTATIN CALCIUM | LEK Pharmaceuticals D.D. (SI) | 2008-04-23 | — | — | EP | disclosed |
| US-7312329-B2 | Process for the preparation of pyrimidine derivatives | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2007-12-25 | — | — | US | disclosed |
| US-7312329-B2 | Process for the preparation of pyrimidine derivatives | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2007-12-25 | — | — | US | disclosed |
| WO-2007017117-A1 | PROCESS FOR THE SYNTHESIS OF ROSUVASTATIN CALCIUM | LEK PHARMACEUTICALS D.D. (SI) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255170-A1 | Process for the Synthesis of Rosuvastatin Calcium | HMGCR, ME1, COASY | HMGCR 1/4885ALDH1A1 1292/4885CYP3A4 151/4885 |
| US-20090275752-A1 | Novel Process for Statins and its Pharmaceutically Acceptable Salts Thereof | HMGCR, NPC1L1, PCSK9 | HMGCR 1/4885ALDH1A1 1466/4885CYP3A4 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.